{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:12:44Z","timestamp":1790626364585,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ministry of Sciences, Research, and Arts in Baden W\u00fcrttemberg"},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Education and Research","award":["BMBF 01EO1303"],"award-info":[{"award-number":["BMBF 01EO1303"]}]},{"name":"German Federal Ministry of Education and Research","award":["BMBF 01EO0803"],"award-info":[{"award-number":["BMBF 01EO0803"]}]},{"name":"CAPES Foundation, Ministry of Education of Brazil","award":["DF 70040-020"],"award-info":[{"award-number":["DF 70040-020"]}]},{"name":"EFIS-IL fellowship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jaut.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T01:45:30Z","timestamp":1477446330000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Impact of tofacitinib treatment on human B-cells in\u00a0vitro and in\u00a0vivo"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-6089","authenticated-orcid":false,"given":"Marta","family":"Rizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Staniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iga","family":"Janowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Troilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Strohmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Erlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2016.10.005_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.10.005_bib2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2016.10.005_bib3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/ard.2005.050385","article-title":"Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment","volume":"65","author":"Walker","year":"2006","journal-title":"Ann. Rheumatic Dis."},{"key":"10.1016\/j.jaut.2016.10.005_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2016.10.005_bib5","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","article-title":"Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes","volume":"24","author":"Riese","year":"2010","journal-title":"Best Pract. Res. Clin. Rheumatology"},{"key":"10.1016\/j.jaut.2016.10.005_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2016.10.005_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X12470753","article-title":"The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential","volume":"5","author":"Cutolo","year":"2013","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.jaut.2016.10.005_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/JIR.S35901","article-title":"Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis","volume":"6","author":"Cutolo","year":"2013","journal-title":"J.\u00a0Inflamm. Res."},{"key":"10.1016\/j.jaut.2016.10.005_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2016.10.005_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.jaut.2016.10.005_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2016.10.005_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI117685","article-title":"The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium","volume":"95","author":"Dechanet","year":"1995","journal-title":"J.\u00a0Clin. Investigation"},{"key":"10.1016\/j.jaut.2016.10.005_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1073\/pnas.93.1.221","article-title":"Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis","volume":"93","author":"Schroder","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2016.10.005_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.autrev.2011.06.010","article-title":"B-cells and their targeting in rheumatoid arthritis\u2013current concepts and future perspectives","volume":"11","author":"Nakken","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.10.005_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.20091706","article-title":"B\u00a0cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans","volume":"207","author":"Avery","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2016.10.005_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02981951","article-title":"Role of Jak kinases and STATs in cytokine signal transduction","volume":"73","author":"Leonard","year":"2001","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jaut.2016.10.005_bib18","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1182\/blood-2011-06-362533","article-title":"IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in\u00a0vivo","volume":"118","author":"Recher","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2016.10.005_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2016.10.005_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ejhg.2008.169","article-title":"STAT3 single-nucleotide polymorphisms and STAT3 mutations associated with hyper-IgE syndrome are not responsible for increased serum IgE serum levels in asthma families","volume":"17","author":"Wjst","year":"2009","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"10.1016\/j.jaut.2016.10.005_bib21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.jaci.2013.01.018","article-title":"Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid","volume":"131","author":"Kienzler","year":"2013","journal-title":"J.\u00a0allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib22","doi-asserted-by":"crossref","first-page":"13945","DOI":"10.1073\/pnas.0903543106","article-title":"B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans","volume":"106","author":"Warnatz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2016.10.005_bib23","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.4049\/jimmunol.0801859","article-title":"Novel human transitional B cell populations revealed by B cell depletion therapy","volume":"182","author":"Palanichamy","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib24","first-page":"1372","article-title":"Processing of gene expression data generated by quantitative real-time RT-PCR","volume":"32","author":"Muller","year":"2002","journal-title":"BioTechniques"},{"key":"10.1016\/j.jaut.2016.10.005_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nri3447","article-title":"The good, the bad and the ugly - TFH cells in human health and disease","volume":"13","author":"Tangye","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ni.3348","article-title":"Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response","volume":"17","author":"Tellier","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","article-title":"Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme","volume":"102","author":"Muramatsu","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2016.10.005_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0092-8674(00)00079-9","article-title":"Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)","volume":"102","author":"Revy","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2016.10.005_bib30","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-y l)-3-oxopropanenitrile (CP-690,550)","volume":"51","author":"Jiang","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jaut.2016.10.005_bib31","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jaut.2016.10.005_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.113.209304","article-title":"Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis","volume":"348","author":"Dowty","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jaut.2016.10.005_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri2491","article-title":"Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling","volume":"9","author":"Herzog","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4049\/jimmunol.1400063","article-title":"Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts","volume":"193","author":"Onda","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.immunol.21.120601.141138","article-title":"Regulatory mechanisms that determine the development and function of plasma cells","volume":"21","author":"Calame","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib36","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.4049\/jimmunol.175.12.7867","article-title":"IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells","volume":"175","author":"Ettinger","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib37","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, a JAK inhibitor, inhibits human B cell activation in\u00a0vitro","volume":"73","author":"Wang","year":"2014","journal-title":"Ann. Rheumatic Dis."},{"key":"10.1016\/j.jaut.2016.10.005_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imlet.2011.02.004","article-title":"Insights into the B cell specific process of immunoglobulin class switch recombination","volume":"138","author":"Kracker","year":"2011","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jaut.2016.10.005_bib39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jaci.2014.02.034","article-title":"Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency","volume":"133","author":"Salzer","year":"2014","journal-title":"J.\u00a0allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1084\/jem.20111229","article-title":"Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome","volume":"210","author":"Kotlarz","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2016.10.005_bib41","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1084\/jem.20130323","article-title":"Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells","volume":"210","author":"Deenick","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2016.10.005_bib42","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.4049\/jimmunol.1302783","article-title":"Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells","volume":"192","author":"Giesecke","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib43","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4049\/jimmunol.182.2.890","article-title":"Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells","volume":"182","author":"Good","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib44","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaut.2016.10.005_bib45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4049\/jimmunol.170.2.686","article-title":"Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses","volume":"170","author":"Tangye","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/TP.0b013e31818bbea7","article-title":"The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients","volume":"87","author":"van Gurp","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jaut.2016.10.005_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br. J. Dermatology"},{"key":"10.1016\/j.jaut.2016.10.005_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2016.10.005_bib49","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/hmg\/2.8.1099","article-title":"The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1","volume":"2","author":"Puck","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jaut.2016.10.005_bib50","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4049\/jimmunol.1301815","article-title":"A\u00a0feeder-free differentiation system identifies autonomously proliferating B cell precursors in human bone marrow","volume":"192","author":"Kraus","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib51","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.4049\/jimmunol.0800489","article-title":"IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow","volume":"182","author":"Parrish","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.10.005_bib52","doi-asserted-by":"crossref","first-page":"e85463","DOI":"10.1371\/journal.pone.0085463","article-title":"Fate of lymphocytes after withdrawal of tofacitinib treatment","volume":"9","author":"Piscianz","year":"2014","journal-title":"PloS One"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116302487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116302487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:15:38Z","timestamp":1760256938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116302487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":52,"alternative-id":["S0896841116302487"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.10.005","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of tofacitinib treatment on human B-cells in\u00a0vitro and in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}